FDA Approves Novo Nordisk's First Oral Wegovy Weight-Loss Pill

The U.S. Food and Drug Administration has approved Novo Nordisk's once-daily oral semaglutide 25 mg tablet, the first pill version of Wegovy cleared for chronic weight management.

“The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according topharmaceutical giant Novo Nordisk”

BBC

Industry and media describe the decision as a major milestone for obesity treatment and for Novo Nordisk's competitive position.

BBC

Reports note the approval follows pivotal late-stage trials and that the drug is slated to reach U.S. pharmacies early in January 2026, with Novo planning regulatory submissions in other regions soon.

Coverage highlights both clinical impact and market implications, from broader access for people who prefer pills to changes in the competitive landscape with rivals such as Eli Lilly still pursuing oral options.

Clinical trial evidence reported across outlets shows substantial weight loss versus placebo, but the exact figures quoted differ between sources.

Some coverage cites the 64‑week study results presented by Novo — an average 16.6% weight loss for participants on the 25 mg dose versus 2.7% for placebo.

bgnes

Other reporting and trial summaries cite roughly 13.6% average loss over about 15 months, with placebo near 2.1–2.2%.

Outlets also note that trial sizes vary by report, for example OASIS‑4 had about 307 adults while other summaries refer to trial populations of around 1,300.

Several sources caution that real‑world effectiveness will need postapproval monitoring.

Coverage emphasizes administration rules, tolerability, and comparative convenience.

“New York, 22 December 2025 – The US Food and Drug Administration has approved a pill version of Novo Nordisk’s blockbuster weight-loss drug Wegovy, marking the first oral GLP-1 medication cleared for obesity treatment and offering a needle-free option for millions seeking to manage their weight”

Central News South Africa

Multiple outlets report that the Wegovy pill must be taken on an empty stomach with only a small sip of water and a 30-minute wait before eating.

That fasting restriction is tied to how the drug is absorbed orally.

Reported common side effects mirror injectable GLP-1s — nausea, diarrhea and other gastrointestinal symptoms — and a minority of trial participants stopped treatment because of adverse effects.

Coverage contrasts Wegovy with rival oral candidates, notably Lilly’s orforglipron, which are described as having no such fasting restriction and therefore could offer a practical adherence advantage.

Sources diverge on how they frame pricing, access, and the broader market impact.

Several outlets report that Novo and U.S. officials recently discussed lower starting-dose pricing and that initial self-pay offers or policy agreements could set starting oral doses near $149–$150 per month through certain channels.

CoinCentral

Other reporting stresses uncertainty about insurance coverage and longer-term affordability.

Market-oriented coverage places the approval in a multi‑billion‑dollar GLP-1 growth story and notes how a pill format could expand the addressable population, while analysts and doctors caution that real-world adoption depends on cost, coverage, and tolerability.